biomed devic servic
diagnost tool
price close busi juli
preview buy-rat look keep go
hold-rat look rebuild credibl
buy rate hold rate set report next monday
tuesday respect close share tear rocket
intra-quart ytd low
flat ytd updat last quarter downgrad stock ahead
print rais pt street-high inch pt
long term look healthi think ok print
believ compani well posit particularli next year
takeaway meet host intra-quart titl growth vector
point right manag emphas investor need
obsess quarterli swing instrument revenu rev rather look
growth rate recur revenu base rev sequenc
array consum grew respect model
believ penetr global sequenc market
earli inning convert higher throughput user novaseq
think may upsid revenue guid possibl rais
call think requir quarter high convict
sustain growth consum array given view
human sequenc popul sequenc liquid
biopsi pharma studi estim peopl genotyp year
to-dat expect growth ancestri continu
appear us consensu revenue estim low
remain one top pick believ prowess exom sequenc
advanc single-cel applic well understood investor
mark upsid street estim
model adj ep vs street rev
y/i slightli q/q vs guidanc modest q/q growth slightli
street model y/i q/q consum
y/ q/q services/oth season step array
y/i q/q instrument
bounc low valuat support trade
street ebitda ntm ep bear case cyno reset hit last
 reduc short interest float think need see clean
cynosur rev q/q model vs last quarter consist
guid beat rev adj ep least reiter guid
model rev vs street guid
in-lin adj ep vs guid think
could tighten guidanc vs street
ep guid vs our/street
us august boston pleas host investor dinner
aug boston ahead annual canaccord genuiti growth confer
august pleas contact us reserv seat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
buy-rat look keep go
hold-rat look rebuild
credibl put rear-view mirror
buy rate hold rate set report next monday
tuesday close respect share tear rocket
intra-quart ytd low
flat ytd updat last downgrad stock ahead
print rais price target street-high inch price
target price target rais use multipl
unchang adj ep estim consensu
price target rais use multipl adj ep
estim
posit buy-rat head print remain sidelin
hold-rat continu view must market leader
nascent next-gen sequenc market given execut number
growth driver believ compani well posit achiev exceed
guid remain hold rate believ compani still
figur cynosur look sign stabil recoveri
cynosur surgic evid build traction breast health dx
model adj ep vs street revenu
y/i flat q/q model novaseq placement recal
report novaseq quarterli basi expect track deliv
rang novaseq year particularli roll newer flow cell
larger custom take order flow cell model y/i
q/q consum includ seq consum y/
q/q services/oth y/i q/q instrument
addit thought ahead call key call
recal beat guid guid street
rais revenue guid addit view
achiev given expect grow consum microarray
consum would surpris see rais guid
arent expect least call earli think
could hear novaseq consum pull-through guidanc rang
worth model novaseq consum pull-through
end context look hiseq consum pull-through
lower end custom transit
 novaseq expect take least sever
quarter even two year play
regardless bullet think import
deliv total consum growth estim total
sequenc consum growth estim y/i
instrument rev rev two year ago
model instrument rev rev consum
look posit commentari around expect average-risk nipt
look updat major popul sequenc initi liquid biopsi
rugd rare undiagnos diseas possibl single-cel sequenc
look color on-going strength dtc consum genet test
model rev vs street
guid in-lin adj ep vs guid look
cynosur rev modestli last quarter think may
see tighten revenue guid vs street
ep guid vs our/street
call
expect either reaffirm like tighten revenu guidanc
rang look like fairli wide rang outcom
expect like guid typic guid
consensu next quarter look rev
y/i q/q base estim
consensu look adj ep penni
consensu estim
look sign stabil medic aesthet cyno segment
think need see least q/q revenu growth cynosur also want
hear credibl narr cynosur sale forc either fulli staf
close fulli staf new rep show sign increas
product take month fulli ramp hope hear
revenu contribut newer tempsur envi radiofrequ platform
launch well updat well flagship sculpsur product
well mona lisa touch recal record huge
goodwil impair charg cynosur acquisit price
net cash
model breast health revenu y/i flat q/q driven
strong ou growth adopt holx higher-end imag
system perform lower-end system competit great
compani like ge roch abbott allergan remain fierc requir
superb execut overcom view much like holx
strateg posit breast health
model gyn/surg rev flat expect surgic perform
better easier comp new leadership new sale forc
incent made chang surgic sale incent priorit
model total diagnost rev flat look evid strength
holx women health test ct/ng hpv trich hbv test
encourag holx strateg posit molecular diagnost enter
compani benefit materi new traction full suit
virolog assay addit expect benefit new flu assay
model skelet health revenu y/i
look commentari continu debt repay outlook share
repurchas activ sales-and-market spend cynosur direct-to-
consum initi breast health busi updat tax
initi beyond big tax reform law put place januari
figur trade ntm consensu ebitda estim recent peak level larger comp trade
factset past perform predict futur result
figur share trade consensu ntm adj ep peak peak peer
factset past perform predict futur result
figur trade ntm consensu adj ep all-tim high trade line premium med-tech stock
factset past perform predict futur result
figur trade ntm street ebitda all-tim high trade line premium med-tech stock
factset past perform predict futur result
figur trade ntm street ev/rev all-tim high trade line premium med-tech stock
factset past perform predict futur result
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
figur detail revenu part revenu instrument famili
figur detail revenu part revenu instrument famili
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
